Norman R. Wasel, MD, FRCPC


Stratica Medical

10140-117 Street NW, Suite 200
Edmonton, Alberta, Canada
T5K 1X3


Specialty: Dermatology

Dr. Norman R. Wasel, Dermatologist Specialist in Psoriasis

Research Interests: Acne, Actinic Keratoses, Atopic Dermatitis, Hyperhidrosis, Psoriasis, Psoriatic Arthritis, Onychomycosis, Rosacea, Seborrheic Dermatitis


Dr. Norman Wasel is a Board Certified Dermatologist in Canada and the United States. He is a licensed Dermatologist in both Alberta and the Northwest Territories. 

Since 2002 Dr. Wasel has been conducting clinical trials at the busiest and largest dermatology clinical research site in Alberta. Dr. Wasel has a large clinical practice which supports his high level of recruitment in clinical trials.

Dr. Wasel has conducted a large number of Phase I, II, III, and IV psoriasis clinical trials. He has conducted psoriasis clinical trials involving the following compounds:

ILV-094, ABT-874(briakinumab), adalimumab, ISA247(voclosporin), CNTO-1275(ustekinumab), etanercept, efalizumab, infliximab, BMS-582949,  LEO 22811, LEO 80190,  onercept, alefacept, RWJ-445380, CC-10004(apremilast), CD 2027, tacalcitol, dovobet, dovonex

Stratica Medical is a highly experienced clinical research facility, successfully completing a Health Canada inspection with a rating of Compliant and no significant findings for a pivotal phase III psoriasis study.

Due to his clinical trial experience Dr. Wasel is a well published author, including a Lancet article on plaque psoriasis in 2008.


Click to view Dr. Norman Wasel's Publications

Papp K, Albrecht L, Barber K, Bourcier M, Dion P-L, Freiman A, Gooderham M, Guenther L, Gulliver W, Hong C, Lynde C, Poulin Y, Siddha S, Toole J, Toth D, Vender R, Wasel N, Wiseman M. An open letter to Health Canada. J Cutan Med Surg 2017; 21(3): 195-6. doi: 10.1177/1203475417704642

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 Dec 15; 375(24): 2335-48. Epub 2016 Sep 30. PMID: 27690741 / doi: 10.1056/NEJMoa1610020

Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg 2016 Jul 15. [Epub ahead of print]. PMID: 27421294

Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III efficacy and safety trial evaluating the effects of apremilast in psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016 Mar 24. [Epub ahead of print]. PMID: 27021239 / doi: 10.1016/j.jaad.2016.02.1164

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 Aug 8; 386(9993):541-51. Epub 2015 Jun 10. PMID: 26072109 / doi: 10.1016/S0140-6736(15)60125-8

Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014 Dec; 171(6):1508-16. Epub 2014 Oct 28. PMID: 24934963 / doi: 10.1111/bjd.13191

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014 Nov; 13(11):1380-6. PMID: 25607706

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; the ERASURE and FIXTURE Study Groups. Secukinumab in plaque psoriasis – Results of two phase 3 trials. N Engl J Med 2014 Jul 24; 37(4): 326-38. Epub 2014 Jul 9. PMID: 25007392 / doi: 10.1056/NEJMoa1314258

Szepietowski J, Papavassilis C, Notter M, Wasel N. Secukinumab efficacy stratified by body weight: A subanalysis from the FIXTURE study. J Am Acad Dermatol 2014 May; 70(5) Supplement 1: AB187

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Vender R, Wasel N, Hsu MC, Szapary P. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol 2013 Oct 1; 12(10): 1122-9. PMID: 24085047

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 Aug 31; 382(9894): 780-9. Epub 2013 Jun 12. PMID: 23769296 / doi: 10.1016/S0140-6736(13)60594-2

Poulin Y, Wasel N, Chan D, Bernstein G, Andrew R, Fraquelli E, Papp K. Evaluating practice patterns for managing moderate to severe plaque psoriasis: Role of the family physician. Can Fam Physician 2012 Jul; 58(7):e390-e400. PMID: 22859642

Albrecht L, Bourcier M, Ashkenas J, Papp K, Shear N, Toole J, Vender R, Wasel N; Canadian Psoriasis Guidelines Committee. Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. J Cutan Med Surg 2011 Nov-Dec; 15(6):309-21. PMID: 22202506

Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011 Jul-Aug; 15(4):210-9. PMID: 21781627

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled double-blind trial. Arch Dermatol 2011 Apr; 147(4):429-436. Epub 2010 Dec 20. PMID: 21173304

Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G and Chan D. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010 Dec; 49(12): 1368-75. PMID 21155084

Papp K, Valenzuela F, Poulin Y, Bernstein G, and Wasel N. Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. J Cutan Med Surg 2010 Jul/Aug; 14(4):167-74. PMID:20642985

Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, Liu Y, Graeber M; Adapalene Lotion Study Group. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2010 Jun; 9(6):639-46. PMID: 20645525

Wasel N, Poulin Y, Andrew R, Chan D, Fraquelli E, Papp K. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009 Nov/Dec; 13(6):294-302. PMID:19919806

Long R, Beatch A, Lee MC, Cheung-Lee M, Wasel N. Lupus vulgaris occurring in a locus minoris resistentiae. J Cutan Med Surg 2009 Nov/Dec; 13(6):313-6. PMID:19919809

Papp K, Bissonnette R, Rosoph L, Wasel N, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008 Apr; 371:1337-42. PMID:18424323

Barankin B. Clinical Tips: Tip 4: When Patients Ask if Cortisone Thins the Skin (Contributed by Wasel N). The Dermatologist 2008 Feb; 16(2).

Barankin B, Wasel N. Treatment of inguinal hyperhidrosis with botulinum toxin type A [letter]. Int J Dermatol 2006 Aug; 45:985-6. PMID:16911393

Barankin B, Taher M, Wasel N. Successful hair transplant of eyebrow alopecia areata. J Cutan Med Surg 2005 Aug; 9(4):162-4. PMID:16502201

Van de Kerkhof PC, Wasel N, Kragballe K, Cambazard F, Murray S. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 2005; 210(4):294-9. PMID:15942215

Barankin B, Metelitsa AI, Schloss EH, Wasel NR. Skin disorders in Ashkenazi Jews: a review. Int J Dermatol 2005 Aug; 44(8):630-5. PMID:16101861

Barankin B, Wasel N. Granulomatous cheilitis – Photo diagnosis. Can J Diagn 2004 Oct; 21(10):49.

Wasel N, Idikio H, Lees G, Krol A, Lin AN. Junctional epidermolysis bullosa with pyloric stenosis presenting with electron microscopic findings suggestive of epidermolysis bullosa simplex. Pediatr Dermatol 2000 Sept/Oct; 17(5):395-3. PMID:11085671

Wasel N.  Sleepless nights and anxious days. Dermatology Times of Canada 2000 Mar; 9(2).

Wasel N. The frustrations of psoriasis. Dermatology Times of Canada 1999 Mar.

Wasel NR, Taher M, Lauzon GJ.  Melanoma cell death induced by sphingosine and betulinic acid. Abstract in Clin Invest Med 1999; 22(4):162-3. 

Wasel N, Schloss E, Lin A.  Minocycline-induced cutaneous pigmentation. J Cutan Med Surg 1998 Oct; 3(2):105-8. PMID:9822786

Triggs-Raine B, Richard M, Wasel N, Prence E, Natowicz M.  A mutational analysis of enzyme-defined Tay-Sachs disease carriers of French Canadian background. Am J Hum Genet 1995 Apr; 56(4):870-9. PMID:7717398

Wasel N, Cao Z, Richard M, Natowicz M, Triggs-Raine B.  Tay-Sachs disease risk in Franco-Americans.  Abstract in Clin Res 1994; 42(3):439A.

Broughton R, Wasel N.  A text-stimuli presentation manager for the IBM PC with ipsatization correction for response sets and reaction times. Behav Res Methods Instrum Comput 1990; 22(4): 421-3.

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.